APTN ADAPTIN BIO, INC.
Company Updates ·
Adaptin Bio said on August 20, 2026 that enrollment has opened for a Phase 1 study of APTN-101 in patients with glioblastoma. The study is being conducted with Duke University and expects to enroll up to 15 adults.
We have not published a story on ADAPTIN BIO, INC. yet. When there is news, it will appear here.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.8 million | $1.8 million |
| Net income (loss) | -$5.2 million | -$3.1 million |
| Cash from operations | -$4.8 million | -$649,283 |
| Cash and equivalents | $459,174 | $34,085 |
ADAPTIN BIO, INC. trades under the ticker APTN on OTC.
ADAPTIN BIO, INC. is listed on OTC.
Our directory records ADAPTIN BIO, INC. under United States.
aibio.space lists ADAPTIN BIO, INC. among 2,820 public biotech companies and publishes its news here as stories appear.
ADAPTIN BIO, INC. reported a net loss of $5.2 million for the fiscal year ended Dec 31, 2025, and used $4.8 million of cash in operations, per its annual report to the SEC.
$1.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$670,488 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on ADAPTIN BIO, INC., dated Aug 20, 2026: "Adaptin Bio opens enrollment in Phase 1 trial of APTN-101 for glioblastoma". Adaptin Bio said on August 20, 2026 that enrollment has opened for a Phase 1 study of APTN-101 in patients with glioblastoma. The study is being conducted with Duke University and expects to enroll up to 15 adults. Source.
From our story of Aug 20, 2026: The release lists, among its risks, the company's ability to raise additional money to fund its operations for at least the next 12 months as a going concern. Source.
Press Follow on this page to add ADAPTIN BIO, INC. to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming ADAPTIN BIO, INC. so far, in Company Updates.
Filed a registration statement for a share offering. SEC Form S-1. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio